European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news